Novel Insights into the Links between N6-Methyladenosine and Regulated Cell Death in Musculoskeletal Diseases

Juanjuan Han,Cuijing Wang,Haolin Yang,Jiayi Luo,Xiaoyi Zhang,Xin-An Zhang
DOI: https://doi.org/10.3390/biom14050514
IF: 6.064
2024-04-25
Biomolecules
Abstract:Musculoskeletal diseases (MSDs), including osteoarthritis (OA), osteosarcoma (OS), multiple myeloma (MM), intervertebral disc degeneration (IDD), osteoporosis (OP), and rheumatoid arthritis (RA), present noteworthy obstacles associated with pain, disability, and impaired quality of life on a global scale. In recent years, it has become increasingly apparent that N6-methyladenosine (m6A) is a key regulator in the expression of genes in a multitude of biological processes. m6A is composed of 0.1–0.4% adenylate residues, especially at the beginning of 3′-UTR near the translation stop codon. The m6A regulator can be classified into three types, namely the "writer", "reader", and "eraser". Studies have shown that the epigenetic modulation of m6A influences mRNA processing, nuclear export, translation, and splicing. Regulated cell death (RCD) is the autonomous and orderly death of cells under genetic control to maintain the stability of the internal environment. Moreover, distorted RCDs are widely used to influence the course of various diseases and receiving increasing attention from researchers. In the past few years, increasing evidence has indicated that m6A can regulate gene expression and thus influence different RCD processes, which has a central role in the etiology and evolution of MSDs. The RCDs currently confirmed to be associated with m6A are autophagy-dependent cell death, apoptosis, necroptosis, pyroptosis, ferroptosis, immunogenic cell death, NETotic cell death and oxeiptosis. The m6A–RCD axis can regulate the inflammatory response in chondrocytes and the invasive and migratory of MM cells to bone remodeling capacity, thereby influencing the development of MSDs. This review gives a complete overview of the regulatory functions on the m6A–RCD axis across muscle, bone, and cartilage. In addition, we also discuss recent advances in the control of RCD by m6A-targeted factors and explore the clinical application prospects of therapies targeting the m6A–RCD in MSD prevention and treatment. These may provide new ideas and directions for understanding the pathophysiological mechanism of MSDs and the clinical prevention and treatment of these diseases.
biochemistry & molecular biology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the association between N6 - methyladenosine (m6A) modification and regulatory cell death (RCD) in musculoskeletal diseases (MSDs). Specifically, the paper aims to reveal how m6A modification affects the pathophysiological mechanisms of musculoskeletal diseases by regulating different types of RCD (such as autophagy - dependent cell death, apoptosis, necroptosis, pyroptosis, ferroptosis, etc.). In addition, the paper also discusses the potential clinical application prospects of m6A modification in these diseases. ### Main problems and objectives of the paper 1. **Reveal the role of m6A modification in MSDs**: - Study how m6A modification regulates gene expression and thus affects the processes of different types of RCD. - Explore the crucial role of m6A modification in the occurrence and development of MSDs. 2. **Understand the molecular mechanisms between m6A modification and RCD**: - Analyze how the "writer", "reader" and "eraser" proteins of m6A modification regulate the expression of RCD - related genes. - Describe the effects of m6A modification on mRNA stability, translation efficiency and splicing. 3. **Explore the clinical application of the m6A - RCD axis in MSDs**: - Evaluate the potential of m6A modification as a treatment target for MSDs. - Discuss the possible application directions of m6A modification in the prevention and treatment of MSDs. ### Key concepts and terms - **m6A modification**: A dynamic and reversible RNA modification regulated by three types of proteins: "writers", "readers" and "erasers". - **Regulatory cell death (RCD)**: A genetically controlled, cell - autonomous and orderly cell death process, including apoptosis, autophagy - dependent cell death, necroptosis, pyroptosis, ferroptosis, etc. - **Musculoskeletal diseases (MSDs)**: Diseases including osteoarthritis (OA), osteosarcoma (OS), multiple myeloma (MM), intervertebral disc degeneration (IDD), osteoporosis (OP) and rheumatoid arthritis (RA), etc. Through in - depth research on the relationship between m6A modification and RCD, this paper provides a new perspective for understanding the pathophysiological mechanisms of MSDs and a theoretical basis for developing new treatment strategies.